NovaBiotics' oral Lynovex improves outcomes in Phase II for CF

NovaBiotics Ltd. (Aberdeen, U.K.) said oral Lynovex cysteamine (formerly NM001) as an adjunct to standard of care (SOC) significantly improved health-related questionnaire scores

Read the full 236 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE